Tuesday, January 14, 2014

Madison Vaccines Incorporated Secures 8 Million Funding Dollars

Madison Vaccines Incorporated secures 8 million dollars to fund activities required to bring a cancer vaccine to market.  Madison Vaccines Incorporated is a growing biotech located on 505 South Rosa Road, Madison Wisconsin 53719. The vaccine is an intervention used in treating a diagnosis of prostate cancer.

The vaccine pTVG-HP is a prostatic acid phosphatase encoding DNA plasmid.  pTVG-HP is a piece of DNA genetic material that contains genetic code for a protein that is made by the prostate gland called prostatic acid (PAP) phosphatase.  Prostatic acid phosphatase is a tumor associated antigen.  The antigen causes the immune system to produce antibodies against it.  Antibodies are recruited by the immune system to identify and neutralize the foreign (cancer) objects.

pTVG-HP is administered to stimulate the body to generate cytotoxic T lymphocyte (CTL) response against prostatic acid phosphatase expressing prostate cancer cells.  The cytotoxic T lymphocyte is a type of white blood cell that attacks and kills cancer cells.

Home Care Path wishes Madison Vaccines Incorporated great success in bringing pTVG-HP to market.

   Home Care Path celebrates 4 years of successfully serving seniors in South Central Wisconsin

 
 

 App  http://appsmakerstore.com/appim/j6kcdet8xvwk4s


Blog  http://homecarepathseniorcare.blogspot.com/

 Home Care Path  www.homecarepath.com and the Wisconsin PATH ALONG model deliver an advanced supportive care service.  Helping seniors in the home, with clinic visits, at the hospital, nursing home and assisted living facility.  Helping seniors downsize with a move in to an adult child's home. 2013 rates are 20.00 per hour.  Simply call 608-432-4286 to schedule an interview.  We can be there when you are working.  We accept long term care insurance.  Services can be tax deductible.  Help with resources and the transition from private payment to public funded programming.  Valuing home and human life 

No comments:

Post a Comment